IMPORTANT TIME-SENSITIVE INFORMATION

NRG-GI002: A Phase II Clinical Trial Platform of Sensitization Utilizing
Total Neoadjuvant Therapy (TNT) in Rectal Cancer

A memorandum regarding the anticipated temporary suspension of accrual is posted on the CTSU website.



 

 

 

Twitter

Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103


Update Profile/Email Address
View this email in your browser
You are receiving this email because of your relationship with NRG Oncology. Please reconfirm your interest in receiving emails from us. If you do not wish to receive any more emails, you can unsubscribe here.